Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
about
Harnessing the protective potential of HIV-1 neutralizing antibodiesRecent strategies targeting HIV glycans in vaccine designDevelopment of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infectionVirological features associated with the development of broadly neutralizing antibodies to HIV-1Molecular evolution of broadly neutralizing Llama antibodies to the CD4-binding site of HIV-1HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM RepertoiresHIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelopeStrategies to guide the antibody affinity maturation processAbility to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire.Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.A pathway to HIV-1 neutralization breadth.Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Native-like Env trimers as a platform for HIV-1 vaccine design.Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Germline-targeting immunogens.In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies.Immunological tolerance as a barrier to protective HIV humoral immunity.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Nanoparticles decorated with viral antigens are more immunogenic at low surface density.Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at its Apex.Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries.Display of the HIV envelope protein at the yeast cell surface for immunogen development
P2860
Q26766153-D0C6D514-B5AA-48EE-BF5A-48678D28CF25Q26823603-86C9CEF5-B620-4EFB-A084-61265E6BBDD6Q27022652-43F73FCA-1836-4B9E-8FAD-D3E9751C3BDBQ27025177-D6C15A91-2848-4E82-8D3F-86D5B82058E5Q27322403-BC71871B-8BC2-4DB3-A95F-201D3FAA36ECQ33753573-FD045919-C137-47B0-9FBC-DB3F7E58E80DQ34101087-60A5CE5C-00B8-46E0-85EB-B0E2326DB7DBQ34915786-D7F7E7A7-3954-4BD9-945C-5906C55CD807Q34991017-4C215BB6-F0FF-4ED9-9087-03CF04A73355Q35685300-C369197C-DC41-44D7-9D89-42AAA401CF8DQ35883727-F91F5ED4-F1B4-48C0-83FC-0E3AD1010785Q35985519-B787DAE3-2633-4AC7-B45D-70E36A27CD30Q36246070-030944D1-6FC0-4FCE-B143-AE933C050FE8Q36303368-6560B22A-763F-4DB3-A478-BF452B95BD7FQ36625139-ED0BF8D2-B503-45F8-8623-B7CD12A9D04CQ36627503-55CB3BCE-FC90-4FCE-8DF2-0EEB60F226EBQ36702114-5287B0B6-1F76-40C6-8A28-E3397F502B5AQ37633417-CF8FF04E-6495-4FCD-A369-7C6C694CA214Q37634061-B98D5D43-61B3-4467-832B-F0BBEC2BCB93Q38219407-ACD3B5D0-800A-4BDE-B8A3-7363EDF912CAQ38665463-8F90F36E-712B-4358-9862-B946D0964675Q38764547-DAFCEDE2-A1DD-465E-BF1A-22E8436C9C57Q38805907-1F9852A8-5A09-45C2-B603-015B304EBCC4Q38862338-A90E7E2D-6B63-4145-BA0E-DE51B592AE4CQ39447992-D09FD31A-52D4-4EEF-9EB0-910C9AE589B3Q40220988-6351EF4C-610A-4B8C-A0D3-0869D4B0D2C1Q40393904-DDEB47A2-2D00-4A99-A989-68F96EDCADE4Q40471380-BF8970FB-75BC-4247-91EA-5849C5A5D8FBQ41924154-080BA9FC-89AF-4E0D-8EEA-E836B6520A0BQ41938263-84ABD337-B60C-440D-87CC-B2BC73C524D9Q52653118-3F2B0F12-C99B-45B5-AA72-326DF08DE001Q58601813-EA3403B8-4604-470D-8B17-A1CB9FFA1C8F
P2860
Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@en
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@nl
type
label
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@en
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@nl
prefLabel
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@en
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@nl
P2093
P2860
P356
P1433
P1476
Diverse recombinant HIV-1 Envs ...... -1 antibodies PG9 and 447-52D.
@en
P2093
Adriana Lippy
Jolene A Glenn
Leonidas Stamatatos
P2860
P304
P356
10.1128/JVI.03228-13
P407
P577
2013-12-18T00:00:00Z